Orthocell Limited (ASX:OCC) Receives Singapore Regulatory Approval for Striate+
Orthocell Limited (ASX:OCC) secures Singapore’s regulatory approval for Striate+, boosting its global market expansion and sales growth.
Tag: Investor Relations
Larvotto Resources Limited (ASX:LRV) Acquires Echidna Gully to Support Hillgrove Mine
Larvotto Resources Limited (ASX:LRV) acquires Echidna Gully to support workforce expansion for the Hillgrove Antimony-Gold Project.
Nimy Resources (ASX:NIM) Signs MoU with Curtin University
Nimy Resources (ASX:NIM) partners with Curtin University to advance gallium research, enhancing its position in the critical minerals market.
Adelong Gold Limited (ASX:ADG) Identifies High-Grade Antimony-Gold Potential at Heyfield Reef Prospect
Adelong Gold (ASX:ADG) identifies significant antimony-gold potential at Heyfield Reef Prospect, Apollo Project VIC, based on high-grade sampling results.
TZ Limited (ASX:TZL) Secures $4M Debt Facility, Finalises Keyvision Acquisition
TZ Limited (ASX:TZL) finalises acquisition of Keyvision Holdings, secures $4M debt facility, and welcomes Keyvision management as strategic shareholders.
Constellation Resources Limited (ASX:CR1) Defines Copper Gold Target at Ularring
Constellation Resources Limited (ASX:CR1) completes a DDIP survey at Ularring, identifying a high-grade copper gold target and announces upcoming drilling plans.
Strickland Metals Limited (ASX:STK) Launches High-Resolution Ground Gravity Survey at Yandal Gold Project
Strickland Metals Limited (ASX:STK) launches a high-resolution gravity survey at Yandal Gold Project and announces an upcoming Mineral Resource update.
Contact Energy (ASX:CEN) Releases February 2025 Operating Report
Contact Energy (ASX:CEN) releases February 2025 report, detailing operational metrics and financial performance.
Volt Resources Limited (ASX:VRC) Announces Remuneration Adjustments and Loan Restructure
Volt Resources Limited (ASX:VRC) announces temporary executive remuneration adjustments and restructures its loan facility to enhance financial resilience.
Chimeric Therapeutics Limited (ASX:CHM) Announces $3.2 Million Entitlement Offer
Chimeric Therapeutics Limited (ASX:CHM) announces a $3.2 million entitlement offer to fund its ongoing cell therapy clinical trials.